Vistide, illustration of injection vial form (not a photo of the actual pack)

Illustrative image.

Vistide

Cidofovir

Prescription required

$6098.00

75mg/mL · 1 vial

BrandBranded medicine· By Gilead Sciences

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warning

WARNING

RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF VISTIDE. CASES OF ACUTE RENAL FAILURE RESULTING IN DIALYSIS AND/OR CONTRIBUTING TO DEATH HAVE OCCURRED WITH AS FEW AS ONE OR TWO DOSES OF VISTIDE. TO REDUCE POSSIBLE NEPHROTOXICITY, INTRAVENOUS PREHYDRATION WITH NORMAL SALINE AND ADMINISTRATION OF PROBENECID MUST BE USED WITH EACH VISTIDE INFUSION. RENAL FUNCTION (SERUM CREATININE AND URINE PROTEIN) MUST BE MONITORED WITHIN 48 HOURS PRIOR TO EACH DOSE OF VISTIDE AND THE DOSE OF VISTIDE MODIFIED FOR CHANGES IN RENAL FUNCTION AS APPROPRIATE (SEE DOSAGE AND ADMINISTRATION ). VISTIDE IS CONTRAINDICATED IN PATIENTS WHO ARE RECEIVING OTHER NEPHROTOXIC AGENTS.

NEUTROPENIA HAS BEEN OBSERVED IN ASSOCIATION WITH VISTIDE TREATMENT. THEREFORE, NEUTROPHIL COUNTS SHOULD BE MONITORED DURING VISTIDE THERAPY.

VISTIDE IS INDICATED ONLY FOR THE TREATMENT OF CMV RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.

IN ANIMAL STUDIES CIDOFOVIR WAS CARCINOGENIC, TERATOGENIC AND CAUSED HYPOSPERMIA (SEE CARCINOGENESIS, MUTAGENESIS, & IMPAIRMENT OF FERTILITY ).

Read this with the rest of the clinical information

About Vistide

Overview

Vistide contains cidofovir and is supplied in a vial for intravenous infusion. It is used to treat CMV retinitis in people with acquired immunodeficiency syndrome (AIDS). Its safety and effectiveness have not been established for other CMV infections, congenital or neonatal CMV disease, or CMV disease in people without HIV.

What it treats

- Cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).

Safety information

Side effects

Frequently reported problems during Vistide treatment included protein in the urine, nausea with or without vomiting, fever, low white blood cell counts, weakness, headache, rash, infections, hair loss, diarrhea, pain, anemia, reduced appetite, shortness of breath, chills and cough. These events were reported during clinical studies and were not all necessarily caused by Vistide. Serious side effects that warrant contacting a doctor include: • Kidney damage, which may show up as protein in the urine or abnormal kidney blood tests. Previous foscarnet treatment has been associated with a higher risk and requires close monitoring. • Severe neutropenia, a very low count of infection-fighting white blood cells. Contact a doctor about fever or signs of infection. • Reduced pressure inside the eye, which can be severe, and inflammation inside the eye (uveitis or iritis). Contact a doctor about eye pain or changes in vision. People with diabetes may have a higher risk of low eye pressure. • Fanconi syndrome, a disorder of kidney function, and metabolic acidosis, a buildup of acid in the blood. Fatal cases of metabolic acidosis associated with liver dysfunction and pancreatitis have been reported. Kidney problems, low white blood cell counts and changes in eye pressure may be detected through monitoring rather than noticeable symptoms.

FDA boxed warning

WARNING

RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF VISTIDE. CASES OF ACUTE RENAL FAILURE RESULTING IN DIALYSIS AND/OR CONTRIBUTING TO DEATH HAVE OCCURRED WITH AS FEW AS ONE OR TWO DOSES OF VISTIDE. TO REDUCE POSSIBLE NEPHROTOXICITY, INTRAVENOUS PREHYDRATION WITH NORMAL SALINE AND ADMINISTRATION OF PROBENECID MUST BE USED WITH EACH VISTIDE INFUSION. RENAL FUNCTION (SERUM CREATININE AND URINE PROTEIN) MUST BE MONITORED WITHIN 48 HOURS PRIOR TO EACH DOSE OF VISTIDE AND THE DOSE OF VISTIDE MODIFIED FOR CHANGES IN RENAL FUNCTION AS APPROPRIATE (SEE DOSAGE AND ADMINISTRATION ). VISTIDE IS CONTRAINDICATED IN PATIENTS WHO ARE RECEIVING OTHER NEPHROTOXIC AGENTS.

NEUTROPENIA HAS BEEN OBSERVED IN ASSOCIATION WITH VISTIDE TREATMENT. THEREFORE, NEUTROPHIL COUNTS SHOULD BE MONITORED DURING VISTIDE THERAPY.

VISTIDE IS INDICATED ONLY FOR THE TREATMENT OF CMV RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.

IN ANIMAL STUDIES CIDOFOVIR WAS CARCINOGENIC, TERATOGENIC AND CAUSED HYPOSPERMIA (SEE CARCINOGENESIS, MUTAGENESIS, & IMPAIRMENT OF FERTILITY ).

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek immediate medical attention for trouble breathing or swelling of the face. - Seek immediate medical attention for eye pain or changes in vision. - Seek immediate medical attention for fever or chills, which may signal an infection. - Seek immediate medical attention for blood in the urine. - Seek immediate medical attention for chest pain or fainting.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Vistide must not be started if blood creatinine is above 1.5 mg/dL, calculated creatinine clearance is 55 mL/min or lower, or urine protein is 100 mg/dL or higher (equivalent to a urine protein result of 2+ or higher). It must not be used while receiving medicines that can damage the kidneys. These medicines must be stopped at least seven days before starting Vistide, under the prescriber’s direction. Vistide must not be used in anyone allergic to cidofovir or with a history of a clinically severe allergic reaction to probenecid or other sulfa-containing medicines. Vistide must never be injected directly into the eye. This has been associated with inflammation of the iris, abnormally low pressure inside the eye and permanent damage to vision.

Using Vistide

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label VISTIDE (CIDOFOVIR) INJECTION [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines